Why AbTheneum
Screen every antibody. Sequence every B cell.
Unlike workflows that select cells first and sequence later, AbTheneum is built to screen and sequence in parallel. That means a broader view of candidate diversity and fewer missed opportunities during hit discovery.
What teams value most:
- A more complete picture of the immune response
- Screening data linked to paired antibody sequences
- Greater flexibility in assay design
- Better support for hit prioritization and decision-making
One example is our First Look Assay, which helps teams assess multiple inputs early and identify where a full discovery campaign may have the strongest opportunity.
Featured Conference Resource
Sliding Scores: First Look Assay
Antibody discovery teams often have multiple options to evaluate, such as different immunization strategies, species, animal strains, tissues, or enrichment methods, but not enough time or budget to take every path into a full campaign.
First Look is designed to help teams compare samples in parallel through antibody screening without full sequencing, providing an early read on relative hit potential so they can focus follow-on work where the opportunity appears strongest.
What it offers:
- Parallel comparison of multiple samples or campaign variables
- Early insight into relative hit rates
- A lower cost way to guide larger discovery decisions
- A practical starting point for prioritizing where to go deeper